… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t(9;22)(q34;q11) rearrangement. The …

… This manuscript presents the scientific insights of the participating attendees, panel … [14]
Moreover, as per NCCN guidelines, B-cells presenting with a CLL/SLL phenotype may be found …

… This manuscript presents the scientific insights of the participating attendees, panel …
Moreover, as per NCCN guidelines, B-cells presenting with a CLL/SLL phenotype may be …

… Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J
Natl … NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr …

… acute lymphoblastic leukemia and acute myeloid leukemia. … testing are recommended by
NCCN guidelines for use in risk … These changes potentially offer insights that could eventually …

… Tyrosine kinase inhibitors (TKIs) have dramatically impacted on the management and
outcome of patients with chronic myeloid leukemia (CML). Long-term overall survival (OS) rates …

… The current NCCN guideline lists omacetaxine as an option for patients with resistance or
intolerance to two or more TKIs and those who progress to AP but not for patients who present …

… [7] and NCCN guidelines [8] for a possible TFR: in the longterm follow-up considered in
the present study, this rate increases to 50%. The hereby reported long-term followup of our …

… Furthermore, the NCCN guidelines recommended that the patients with EMR failure at 3
months of imatinib therapy switched to the other TKIs for the maximum benefit 2 . For this reason…

Background Both ibrutinib and chlorambucil, used alone or in combination, have been used
for first-line treatment for CLL. However, a comprehensive comparison among different CLL …